Daniele Derudas - How I treat extramedullary disease and plasma cell leukemia
13:06
Daniele Derudas - How I treat extramedullary disease and plasma cell leukemia
Жыл бұрын
Elias Jabbour - How I treat the older adult with ALL
14:30
Elias Jabbour - How I treat the older adult with ALL
Жыл бұрын
Naval Daver - Mutation Profiling of AML Patients
17:22
Naval Daver - Mutation Profiling of AML Patients
Жыл бұрын
Nicola Polverelli - How I treat MF candidates for transplant
13:27
Nicola Polverelli - How I treat MF candidates for transplant
Жыл бұрын
Guido Gini - Management and Novel Treatment Approaches in MCL
7:46
Guido Gini - Management and Novel Treatment Approaches in MCL
Жыл бұрын
F.Da Ros - New insights in HBMMSC migration:the response to plasma bone marrow and the role of IRE1A
8:24
F.Da Ros - New insights in HBMMSC migration:the response to plasma bone marrow and the role of IRE1A
Жыл бұрын
Tapan M. Kadia - Non-Intensive Treatment of Older Unfit Patients with AML
15:59
Tapan M. Kadia - Non-Intensive Treatment of Older Unfit Patients with AML
Жыл бұрын
Claudio Cerchione - Agile: phase 3 study of Ivosidenib + Azacitidine vs Placebo + Azacitidine
8:05
Claudio Cerchione - Agile: phase 3 study of Ivosidenib + Azacitidine vs Placebo + Azacitidine
Жыл бұрын
G.Marconi - Select-MDS-1 Trial in progress: Tamibarotene/Azacitidine vs Placebo/Azacitidine
6:12
G.Marconi - Select-MDS-1 Trial in progress: Tamibarotene/Azacitidine vs Placebo/Azacitidine
Жыл бұрын
Naval Daver - Pivekimab sunirine (PVEK, IMGN632) triplet with Azacitidine and Venetoclax
10:25
Naval Daver - Pivekimab sunirine (PVEK, IMGN632) triplet with Azacitidine and Venetoclax
Жыл бұрын
Alessandro Rambaldi - Present and future Prespectives for Cellular Therapy in AML
20:11
Alessandro Rambaldi - Present and future Prespectives for Cellular Therapy in AML
Жыл бұрын
A.Scialdone - Role of BCOR and DNMT3A cooperation in the epigenetic signature of AML
9:58
A.Scialdone - Role of BCOR and DNMT3A cooperation in the epigenetic signature of AML
Жыл бұрын
E.Lombardi - SRY-BOX transcription factor 4 as a target for Multiple Myeloma new theapeutic strategy
8:26
E.Lombardi - SRY-BOX transcription factor 4 as a target for Multiple Myeloma new theapeutic strategy
Жыл бұрын
Cirino Botta - Targeting the bone marrow microenvironment in Multiple Myeloma
14:09
Cirino Botta - Targeting the bone marrow microenvironment in Multiple Myeloma
Жыл бұрын
Giuliano Bolondi - The dark side of CAR-T: the point of view from reanimation room
11:10
Giuliano Bolondi - The dark side of CAR-T: the point of view from reanimation room
Жыл бұрын
Giuseppe Saglio - The history of Chronic Myeloid Leukemia: from nightmare to the cure
16:34
Giuseppe Saglio - The history of Chronic Myeloid Leukemia: from nightmare to the cure
Жыл бұрын
L.Cicconi - Therapy-Related Myeloid Neoplasm after MM in the era of new drugs: a retrospective study
8:48
L.Cicconi - Therapy-Related Myeloid Neoplasm after MM in the era of new drugs: a retrospective study
Жыл бұрын
Guillermo Garcia-Manero - Management of Higher Risk MDS in 2022 at MDACC: a total approach
20:30
Guillermo Garcia-Manero - Management of Higher Risk MDS in 2022 at MDACC: a total approach
Жыл бұрын
Elias Jabbour - How I treat CML at MD ANDERSON CANCER CENTER in 2022
16:32
Elias Jabbour - How I treat CML at MD ANDERSON CANCER CENTER in 2022
Жыл бұрын
Giuseppe Saglio - State of the art and next questions in CML therapy
26:45
Giuseppe Saglio - State of the art and next questions in CML therapy
Жыл бұрын
C.Papayannidis- Harbor: a phase 2/3 study of BLU-263 in patients with Indolent Systemic Mastocytosis
6:15
C.Papayannidis- Harbor: a phase 2/3 study of BLU-263 in patients with Indolent Systemic Mastocytosis
Жыл бұрын
Giovanni Martinelli - Mutations in AML and the importance of molecular testing
11:33
Giovanni Martinelli - Mutations in AML and the importance of molecular testing
Жыл бұрын
Niccolò Bolli - Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?
15:21
Niccolò Bolli - Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?
Жыл бұрын
Carolina Terragna - MRD assessment in MM: Should we? When? Why?
12:50
Carolina Terragna - MRD assessment in MM: Should we? When? Why?
Жыл бұрын
Adrian Mosquera - Artificial Intelligence: applications in Multiple Myeloma
17:25
Adrian Mosquera - Artificial Intelligence: applications in Multiple Myeloma
Жыл бұрын
Sebastiano Giallongo - Epigenetic changes in MDS derived mesenchymal stromal cells
8:27
Sebastiano Giallongo - Epigenetic changes in MDS derived mesenchymal stromal cells
Жыл бұрын
Ayalew Tefferi - Essential Thrombocythemia
10:38
Ayalew Tefferi - Essential Thrombocythemia
Жыл бұрын
Enrico La Spina - Ferroptosis as a new off-target effect of BCMA-targeted Immunotherapy in MM
9:21
Enrico La Spina - Ferroptosis as a new off-target effect of BCMA-targeted Immunotherapy in MM
Жыл бұрын
Naval Daver - FLT3 mutations in AML
18:58
Naval Daver - FLT3 mutations in AML
Жыл бұрын
Пікірлер